MedTrace Logo

Study of Descartes-30 in Acute Respiratory Distress Syndrome

NCT04524962 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-10-29

Study results available
· View outcomes & findings →

Summary

Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19

Conditions

  • Acute Respiratory Distress Syndrome
  • Covid19

Interventions

BIOLOGICAL

Descartes 30

Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2022-09-09
Completion
2023-09-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04524962 on ClinicalTrials.gov